BONANNO, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.870
AS - Asia 2.512
EU - Europa 1.795
SA - Sud America 691
AF - Africa 476
OC - Oceania 58
Continente sconosciuto - Info sul continente non disponibili 31
Totale 11.433
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.601
SG - Singapore 903
BR - Brasile 504
IT - Italia 468
CN - Cina 416
HK - Hong Kong 390
DE - Germania 191
FI - Finlandia 143
VN - Vietnam 142
SE - Svezia 113
NL - Olanda 100
PL - Polonia 99
GB - Regno Unito 91
IN - India 86
RU - Federazione Russa 78
FR - Francia 77
KR - Corea 49
AT - Austria 42
TR - Turchia 39
AR - Argentina 37
EC - Ecuador 31
IQ - Iraq 30
ID - Indonesia 26
UA - Ucraina 26
PY - Paraguay 25
MX - Messico 24
CA - Canada 23
ES - Italia 23
CI - Costa d'Avorio 22
JO - Giordania 22
LB - Libano 22
PE - Perù 21
AE - Emirati Arabi Uniti 20
AO - Angola 20
KH - Cambogia 20
AD - Andorra 19
GP - Guadalupe 19
TN - Tunisia 19
TT - Trinidad e Tobago 19
YT - Mayotte 19
BE - Belgio 18
CH - Svizzera 18
CO - Colombia 18
IL - Israele 18
JP - Giappone 18
BD - Bangladesh 17
CZ - Repubblica Ceca 17
IE - Irlanda 17
TW - Taiwan 17
XK - ???statistics.table.value.countryCode.XK??? 17
AL - Albania 16
BA - Bosnia-Erzegovina 16
CY - Cipro 16
MA - Marocco 16
MD - Moldavia 16
PK - Pakistan 16
PT - Portogallo 16
RO - Romania 16
SA - Arabia Saudita 16
YE - Yemen 16
BB - Barbados 15
CR - Costa Rica 15
EE - Estonia 15
GT - Guatemala 15
KE - Kenya 15
RE - Reunion 15
SN - Senegal 15
ZA - Sudafrica 15
CV - Capo Verde 14
DK - Danimarca 14
DZ - Algeria 14
GE - Georgia 14
NP - Nepal 14
PS - Palestinian Territory 14
UZ - Uzbekistan 14
BF - Burkina Faso 13
BO - Bolivia 13
BS - Bahamas 13
CW - ???statistics.table.value.countryCode.CW??? 13
GH - Ghana 13
HN - Honduras 13
JM - Giamaica 13
LA - Repubblica Popolare Democratica del Laos 13
MW - Malawi 13
NO - Norvegia 13
PH - Filippine 13
RS - Serbia 13
UG - Uganda 13
ZW - Zimbabwe 13
AF - Afghanistan, Repubblica islamica di 12
AM - Armenia 12
AZ - Azerbaigian 12
CM - Camerun 12
DO - Repubblica Dominicana 12
ET - Etiopia 12
GR - Grecia 12
ME - Montenegro 12
MN - Mongolia 12
MZ - Mozambico 12
NA - Namibia 12
Totale 10.886
Salva come PNG Salva come JPEG
Città #
Fairfield 783
Ashburn 634
Singapore 581
Woodbridge 471
Chandler 397
Hong Kong 368
Houston 350
Cambridge 296
Ann Arbor 277
Seattle 267
Wilmington 221
Santa Clara 220
Boardman 130
Beijing 121
Padova 102
San Diego 86
Bytom 74
Helsinki 74
Hefei 66
Princeton 66
Los Angeles 63
New York 59
Medford 58
Munich 56
Milan 51
Des Moines 46
São Paulo 43
Roxbury 42
Buffalo 41
Dong Ket 41
Ho Chi Minh City 39
Seoul 38
Nuremberg 36
Arezzo 32
Chicago 30
Redondo Beach 24
Amman 22
Turku 22
Abidjan 21
Lappeenranta 21
Jacksonville 20
Pune 20
London 19
Dallas 18
Hanoi 18
Luanda 18
Ogden 18
Andorra la Vella 17
Brooklyn 17
Falkenstein 17
Nanjing 17
Rio de Janeiro 17
Warsaw 17
Dublin 16
Phnom Penh 16
Columbus 15
Dakar 15
Lima 15
Nairobi 15
Frankfurt am Main 14
Guayaquil 14
Istanbul 14
Rome 14
Tashkent 14
Baghdad 13
Kampala 13
Nassau 13
Vienna 13
Baku 12
Boston 12
Bridgetown 12
Harare 12
Podgorica 12
San José 12
Stockholm 12
Ulan Bator 12
Accra 11
Atlanta 11
Djibouti 11
Lusaka 11
Montevideo 11
Nanchang 11
Praia 11
Tallinn 11
Tbilisi 11
Washington 11
Athens 10
Bishkek 10
Brasília 10
Dili 10
Dushanbe 10
Guangzhou 10
Kingstown 10
Les Abymes 10
Libreville 10
Lilongwe 10
Panama City 10
Papeete 10
Port Moresby 10
Pristina 10
Totale 7.162
Salva come PNG Salva come JPEG
Nome #
211P: Inflammatory cells characterization and localization in malignant pleural mesothelioma (MPM) tissue samples: Correlation with histologic subtype and prognosis 223
28P Different genetic profiling in lung adenocarcinoma of smokers with and without chronic obstructive pulmonary disease (COPD): An exploratory analysis by next generation sequencing (NGS) 214
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study) 206
166P: Non-small cell lung cancer (NSCLC) patients with rare or complex epidermal growth factor receptor (EGFR) mutations: A single institution series 197
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes 192
Does Induction Therapy Increase Anastomotic Complications in Bronchial Sleeve Resections? 185
Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman 184
Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature 176
Neutrophil-lymphocyte ratio is prognostic in early stage resected small-cell lung cancer 171
Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature 168
Notch3 signalling promotes tumour growth in colorectal cancer 167
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations 166
Immunotherapy in small-cell lung cancer: From molecular promises to clinical challenges 163
77P Glycolytic marker monocarboxylate transporter 4 (MCT4) and outcome to bevacizumab (bev): An exploratory analysis in advanced non-small cell lung cancer (A-NSCLC) 162
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome 162
Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment 157
Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter? 155
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors 153
LKB1 expression correlates with increased survival in advanced non-small cell lung cancer patients treated with chemotherapy and bevacizumab 146
18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy 143
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer 141
Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC 141
Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer 139
Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer 135
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study 135
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 135
Immunotherapy in SCLC: Exceptional Clinical Benefit and Abscopal Pneumonitis After Radiotherapy 134
Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectives 133
Squamous cell carcinomas of the lung and of the head and neck: New insights on molecular characterization 133
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy 131
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines 129
Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors 127
Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: A mono-institutional experience 125
Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150 120
Lung cancer (LC) in HIV positive patients: Pathogenic features and implications for treatment 119
119P The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced non-small cell lung cancer (aNSCLC) patients (pts) 118
Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancer 117
Notch3 signalling promotes tumour growth in colorectal cancer 116
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 116
Therapeutic approaches for T790M mutation positive non-small-cell lung cancer 115
1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI) 115
51P Liver kinase B1 (LKB1) and phosphorylated AMP kinase (AMPK) expression in small cell lung cancer (SCLC): Association with prognosis and tumour immune microenvironment (TIME) features 115
Potentialities of liquid biopsy in advanced non-small cell lung cancer (aNSCLC): Early evaluation of sentinel mutations in plasma and outcome of patients treated with immunotherapy 115
Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification 114
Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs? 109
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 108
Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future? 108
SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer 106
Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel) 106
Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. 105
Novel Nuclear Medicine Imaging Applications in Immuno-Oncology 102
Detection of loss of heterozygosity in cfDNA of advanced EGFR-or KRAS-mutated non-small-cell lung cancer patients 102
Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients 101
The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. 100
Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer 99
Plasma next-generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs): Impact of STK11 and TP53 mutations on outcome 99
Efficacy of osimertinib and the role of sequential liquid biopsy in patients diagnosed with NSCLC harboring EGFR and BRAF mutations at baseline: insights from two case reports 98
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards 97
EGFR T790M testing through repeated liquid biopsy over time: a real-world multicentric retrospective experience 96
A pathological complete response after preoperative chemotherapy with carboplatin and pemetrexed in malignant pleural mesothelioma: A case report. 96
Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting 95
Circulating cytokines as predictors of response to immune checkpoint inhibitors (ICIs) in patients (pts) with melanoma (Mel) and non–small cell lung cancer (NSCLC) 93
The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy. 93
Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors 90
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg? 90
Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience 89
The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies 88
Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM). 88
Implementation of next generation sequencing-based liquid biopsy for clinical molecular diagnostics in non-small cell lung cancer (Nsclc) patients 88
Binary classification of copy number alteration profiles in liquid biopsy with potential clinical impact in advanced NSCLC 87
Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of Patients with Non-small Cell Lung Cancer: Pretreatment Predictors and Correlation With Outcome 87
Longitudinal liquid biopsy predicts clinical benefit from immunotherapy in advanced non-small cell lung cancer 85
Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab 81
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World 77
MAPK pathway activating alteration and immunotherapy efficacy in squamous cell lung carcinoma: results from the randomized, prospective SQUINT trial 76
Extensive-stage small-cell lung cancer in patients receiving atezolizumab plus carboplatin-etoposide: stratification of outcome based on a composite score that combines gene expression profiling and immune characterization of microenvironment 75
Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report 74
Treatment strategies for locally advanced non-small cell lung cancer in elderly patients: Translating scientific evidence into clinical practice 74
Role of genotyping in non-small cell lung cancer treatment: current status. 73
Osimertinib in Resected EGFR -Mutated Non-Small-Cell Lung Cancer 72
Immune-related adverse events in patients treated with immunotherapy for locally advanced or metastatic NSCLC in real-world settings: a systematic review and meta-analysis 70
Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World 69
Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemotherapy: an hypothesis generating study (CATS/ML43257) 69
The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments 66
Secondary prevention and treatment innovation of early stage non-small cell lung cancer: Impact on diagnostic-therapeutic pathway from a multidisciplinary perspective 64
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor???Mutated Non???Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial 61
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer 61
The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer 61
Liver kinase B1 expression is associated with improved prognosis and tumor immune microenvironment features in small cell lung cancer 60
Assessment of chromosomal rearrangements helps to differentiate multiple lung primary cancers from metastases 60
Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis 60
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer 59
Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel Meeting 58
Prospective Validation of the Italian Alliance Against Cancer Lung Panel in Patients With Advanced Non–Small-Cell Lung Cancer 57
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non???Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial 53
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial 52
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase II NeoCOAST-2 trial 51
Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib 50
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC 49
Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients 47
Totale 10.992
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.506
article - articoli 41.506
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 83.012
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021929 0 0 34 25 28 126 224 92 120 101 61 118
2021/20221.161 61 121 111 59 109 132 130 62 54 58 71 193
2022/2023779 126 105 29 113 93 78 9 48 111 17 44 6
2023/2024821 33 85 74 59 44 123 37 122 71 35 73 65
2024/20253.188 14 289 153 130 399 80 101 274 248 196 492 812
2025/20263.044 662 969 1.413 0 0 0 0 0 0 0 0 0
Totale 11.618